Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 07

350P - Postoperative histopathological, clinical and molecular risk score for patients with colorectal liver metastases

Date

10 Sep 2022

Session

Poster session 07

Topics

Tumour Immunology;  Pathology/Molecular Biology;  Multi-Disciplinary and Multi-Professional Cancer Care;  Surgical Oncology

Tumour Site

Colon and Rectal Cancer

Presenters

Berta Martin Cullell

Citation

Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048

Authors

B. Martin Cullell1, A.C. Virgili Manrique2, P. Riera3, C. Fumagalli4, A. Sebio Garcia1, O. Mirallas5, F. Pelegrin2, S. Sánchez-Cabús6, V. Molina6, A. Gonzalez7, J. Szafranska7, D. Paez8

Author affiliations

  • 1 Dept. Oncology, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 2 Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 3 Genetics Department / Pharmacy Department, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 4 Dept. Pathology, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 5 Medical Oncology Department, Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 6 Surgery Department, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 7 Pathology Department, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 8 Dept. Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 350P

Background

Hepatic resection is considered the optimal potentially curative treatment for colorectal liver metastases (LM). The Genetic And Morphological Evaluation (GAME) score, which includes KRAS status, tumor burden score, CEA, lymph node metastases and extrahepatic disease, has been proposed as a preoperative tool to select patients (pts) for liver resection. Nevertheless, histological characteristics of LM have been presented as potential prognostic biomarkers to be considered after resection. This study aimed to create a postoperative score including histological characteristics.

Methods

Clinical and pathological data were collected from 146 metastatic colorectal cancer pts undergoing liver resection between 2004 and 2019 at Hospital de Sant Pau. Histopathological changes in liver parenchyma such as immune phenotype (IP) and histological growth pattern (HGP) were documented to identify potential prognostic factors. We calculated the GAME score of each patient and added the histological characteristics that had a prognostic value in the multivariable analysis.

Results

Of the 146 LM analyzed, twenty-three pts had a desmoplastic HGP (16%), thirty-one (22%) had a desertic IP and a fibrotic capsule was described in 22.5% of the cases. In the univariable analysis, the desmoplastic HGP and the fibrotic capsule was associated with a better overall survival (OS) (102 vs 49.3 months, HR 0.44 95% CI 0.23-0.86; p= 0.013 and 89.3 vs 46.9 months; HR 0.56 95% CI 0.33-0.98; p=0.037). The desertic IP was associated with a shorter OS (34.2 vs 58.3 months; HR 1.77 CI 1.1-2.8; p= 0.01) and remained significant in the multivariable analysis (HR 1.95, CI 95% 1.16-3.23; p= 0.012). We added 1 point to the original GAME score if a desertic immune phenotype was observed, and pts were classified in three risk groups with significant differences in survival. The high-risk group (score ≥4) had a recurrence free survival (RFS) and OS of 12.7 and 36.6 months vs 30.7 and 89.3 months in the low-risk group (score 0-1), respectively (p<0.001 and p=0.007).

Conclusions

The desertic immune phenotype in liver metastasis of CRC has a bad prognostic value and could be considered to assess adjuvant treatment after hepatic resection.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

B. Martin Cullell: Financial Interests, Personal, Training, Travel expenses: ROVI ; Financial Interests, Personal, Training: Pierre Fabre. O. Mirallas: Financial Interests, Personal, Invited Speaker: ROVI, Roche, Kyowa Kirin, Grupo Pacifico; Other, Travel Expenses: Kyowa Kirin; Other, Travel Expenses and Conference Fee: Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.